⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3645652 | 0.80 | ALDH1A1 (0.33) | — | |
| SCHEMBL5752168 | 0.64 | — | — | |
| SCHEMBL5165263 | 0.60 | ALDH1A1 (0.44) | — | |
| SCHEMBL5320280 | 0.60 | — | — | |
| SCHEMBL13735762 | 0.60 | ALDH1A1 (0.65) | — | |
| SCHEMBL3670371 | 0.60 | ALDH1A1 (0.32) | — | |
| SCHEMBL13735766 | 0.59 | ALDH1A1 (0.63) | — | |
| SCHEMBL11279379 | 0.57 | MEN1 (0.34) | — | |
| SCHEMBL5742205 | 0.55 | ALDH1A1 (0.52) | — | |
| SCHEMBL9708912 | 0.53 | ALDH1A1 (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3681503-A1 | PROTEIN KINASE C INHIBITORS FOR TREATMENT OF UVEAL MELANOMA | Novartis AG (CH) | 2020-07-22 | — | — | EP | claimed |
| WO-2019053595-A1 | PROTEIN KINASE C INHIBITORS FOR TREATMENT OF UVEAL MELANOMA | NOVARTIS AG (CH) | 2019-03-21 | — | — | WO | claimed |
| EP-2807164-A1 | IMIDAZOPYRROLIDINONE COMPOUNDS | Novartis AG (CH) | 2014-12-03 | — | — | EP | claimed |
| WO-2013111105-A1 | IMIDAZOPYRROLIDINONE COMPOUNDS | NOVARTIS AG (CH) | 2013-08-01 | — | — | WO | claimed |
| US-12194031-B2 | Compounds for use in regulating follicle maturation | AARHUS UNIVERSITET (DK) | 2025-01-14 | — | — | US | disclosed |
| EP-4274567-A1 | FORMS AND FORMULATIONS OF A TYROSINE KINASE NON-RECEPTOR 1 (TNK1) INHIBITOR | Sumitomo Pharma Oncology, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| US-20230285375-A1 | COMPOUNDS FOR USE IN REGULATING FOLLICLE MATURATION | AARHUS UNIVERSITET (DK) | 2023-09-14 | — | — | US | disclosed |
| US-11666561-B2 | Compounds for use in regulating follicle maturation | AARHUS UNIVERSITET (DK) | 2023-06-06 | — | — | US | disclosed |
| WO-2023067483-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING AN MDM2 INHIBITOR, A BCL2 INHIBITOR AND A HYPOMETHYLATING AGENT AND USES THEREOF FOR THE TREATMENT OF HAEMATOLOGICAL MALIGNANCIES | NOVARTIS AG (CH) | 2023-04-27 | — | — | WO | disclosed |
| WO-2022150801-A1 | FORMS AND FORMULATIONS OF A TYROSINE KINASE NON-RECEPTOR 1 (TNK1) INHIBITOR | SUMITOMO PHARMA ONCOLOGY, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
| EP-3897648-A1 | EXTENDED LOW DOSE REGIMENS FOR MDM2 INHIBITORS | Novartis AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| WO-2020128892-A1 | EXTENDED LOW DOSE REGIMENS FOR MDM2 INHIBITORS | NOVARTIS AG (CH) | 2020-06-25 | — | — | WO | disclosed |
| EP-3064502-A1 | IMIDAZOPYRROLIDINONE COMPOUNDS | Novartis AG (CH) | 2016-09-07 | — | — | EP | disclosed |
| WO-2015084804-A1 | COMBINATION OF MDM2 INHIBITOR AND BRAF INHIBITOR AND THEIR USE | NOVARTIS AG (CH) | 2015-06-11 | — | — | WO | disclosed |
| EP-1622909-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | Pfizer Products Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004094429-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2004-11-04 | — | — | WO | disclosed |